Abstract:Obesity is a major global public health challenge and a leading cause of multiple metabolic disorders, including hypertension and diabetes. In China, more than half of the adult population is overweight or obese. While anti-obesity pharmacotherapies (such as GLP-1 receptor agonists) and bariatric surgery have both advanced rapidly, strategies for integrating these two modalities remain unclear. In particular, controversies persist regarding surgical eligibility after drug discontinuation, and standardized clinical guidelines are lacking. In July 2025, the International Federation for the Surgery of Obesity and Metabolic Disorders released the world's first statement focusing on "metabolic bariatric surgery after pharmacotherapy-induced weight loss", which emphasizes the chronic disease model of obesity management and clarifies the synergistic relationship between pharmacotherapy and surgery. This article interprets the statement from the perspectives of treatment strategies, surgical eligibility, and drug-surgery coordination, aiming to provide evidence-based reference for clinicians and to promote standardized, integrated obesity management.